Fabry's Disease Pipeline Analysis 2018: Major Players are Actelion Pharmaceuticals, Sanofi, Amicus Therapeutics, Protalix and Shire

DUBLIN, June 8, 2018 /PRNewswire/ --

The "Fabry's Disease Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

Fabry's Disease Pipeline Analysis report covers 20 drugs currently in different phases of development. Fabry's disease is a rare genetic disorder caused mostly in males than females due to the deficiency of the alpha-galactosidase A (a-Gal A) enzyme which causes a build-up of a type of fat, globotriaosylceramide (Gb3, or GL-3) in the body. It is also categorised as a type of lysosomal storage disorder. The disease affects skin, eyes, gastrointestinal system, kidney, heart, brain and nervous system among other body parts.

The report provides Fabry's Disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Actelion Pharmaceuticals Ltd, Sanofi, Amicus Therapeutics, Inc., Protalix and Shire among others.

Scope:

• By Company
• By Phase
• By Molecule Type
• By Region
• By Route of Administration

Key Topics Covered:

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

• Actelion Pharmaceuticals Ltd
• Protalix
• Shire
• Amicus Therapeutics, Inc.
• Resverlogix Corp.
• Idorsia Pharmaceuticals Ltd
• AVROBIO, Inc
• Greenovation Biotech GmbH
• JCR Pharmaceuticals Co., Ltd.
• Pharming Group NV
• Sangamo Therapeutics, Inc.
• O&O Alpan, LLC.
• Sanofi
• GREEN CROSS CORP.
• BIOSIDUS
• Neuraltus Pharmaceuticals, Inc.
• BioMarin
• Alexion
• Sigilon Therapeutics, Inc.
• AMO Pharma
  

For more information about this report visit https://www.researchandmarkets.com/research/rvvxj7/fabrys_disease?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/fabrys-disease-pipeline-analysis-2018-major-players-are-actelion-pharmaceuticals-sanofi-amicus-therapeutics-protalix-and-shire-300662488.html

SOURCE Research and Markets